(Q44214968)

English

Pfizer's first-in-class JAK inhibitor pricey for rheumatoid arthritis market

scientific article published in January 2013

In more languages

edit

Statements

instance of

scholarly article

1 reference

stated in

Europe PubMed Central

30 November 2017

Pfizer's first-in-class JAK inhibitor pricey for rheumatoid arthritis market (English)

1 reference

stated in

Europe PubMed Central

30 November 2017

1 reference

Ken Garber

1

1 reference

stated in

Europe PubMed Central

30 November 2017

1 January 2013

1 reference

stated in

Europe PubMed Central

30 November 2017

1 reference

Europe PubMed Central

30 November 2017

31

1 reference

stated in

Europe PubMed Central

30 November 2017

1

1 reference

stated in

Europe PubMed Central

30 November 2017

3-4

1 reference

stated in

Europe PubMed Central

30 November 2017

https://scigraph.springernature.com/pub.10.1038/nbt0113-3

0 references

cites work

Tofacitinib or Adalimumab versus Placebo in Rheumatoid Arthritis

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1038%2FNBT0113-3

retrieved

21 January 2018

Pfizer's JAK inhibitor sails through phase 3 in rheumatoid arthritis

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/23302910

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

DOI

10.1038/NBT0113-3

1 reference

stated in

Europe PubMed Central

30 November 2017

1 reference

Europe PubMed Central

PubMed ID

23302910

retrieved

30 November 2017

(Q44214968)

Pfizer's first-in-class JAK inhibitor pricey for rheumatoid arthritis market

Statements

Identifiers

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)